Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer-Reference-Cited by-同舟云学术

Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer

Published:2017-09-07 Issue:1 Volume:36 Page:
ISSN:1756-9966
Container-title:Journal of Experimental & Clinical Cancer Research
language:en
Short-container-title:J Exp Clin Cancer Res

Author:

Englinger Bernhard,Kallus Sebastian,Senkiv Julia,Heilos Daniela,Gabler Lisa,van Schoonhoven Sushilla,Terenzi Alessio,Moser Patrick,Pirker Christine,Timelthaler Gerald,Jäger Walter,Kowol Christian R.,Heffeter Petra,Grusch Michael,Berger Walter

Funder

Austrian Science Fund

Fonds of the City of Vienna for Innovative Cancer Research

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s13046-017-0592-3.pdf

Reference43 articles.

1. Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014;34:280–300.

2. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–29.